Dr. Rebecca Dent shared TROPION-Breast02 results:
Dato-DXd outdid chemo as 1st line treatment for metastatic TNBC patients ineligible for immunotherapy
✅ Longer survival: 24 vs 18.7 mo; 21% ⬇️death risk
✅ Cancer stayed controlled longer: 9.6 vs 5.2 mo (4/4)

Dr. Javier Cortes on ASCENT-03: Sacituzumab govitecan vs chemo as 1st treatment for metastatic TNBC ineligible for immunotherapy
✅ Cancer stayed controlled longer: 9.7 vs 6.9 mo ⬇️38% risk of progression
✅ longer lasting response to treatment
✅ Fewer stopped treatment 4% vs 12%

Dr. Sibylle Loibl shared DESTINY-Breast09 subgroup results:
T-DXd + pertuzumab as 1st treatment for HER2+ MBC outperformed standard therapy regardless of:
✅ Prior treatment
✅ Hormone receptor status

✅ PIK3CA mutations

Dr. Charles Geyer presented DESTINY-Breast05: T-DXd vs T-DM1 in HER2+ early BC given after initial treatment for those who have cancer remaining after neoadjuvant treatment.
✅ T-DXd cut recurrence risk by ~50%
💊 T-DXd poised to replace T-DM1 as SOC (5/5)

Dr. Nadia Harbeck shared DESTINY-Breast11 results: Neoadjuvant T-DXd with & w/o THP performed better than anthracycline-based chemo in high-risk HER2+ early BC
📈 Pathologic complete response 67% vs 56% (+11%)
✅ Fewer adverse events, less cardiac toxicity
(4/5)

Dr. Sara Hurvitz presented VIKTORIA-1, where gedatolisib + fulvestrant ± palbociclib significantly extended progression-free survival for HR+/HER2-, PIK3CA wild-type advanced BC
✅ Triplet: 9.3 months vs 2
✅ Doublet: 7.4 vs 2
📍Possible new option post-CDK4/6 treatment( 3/5)

Dr. Erica Mayer presented evERA trial data: Oral SERD giredestrant + everolimus doubled response rates & cut risk of progression by ~60% vs standard HT after CDK4/6 inhibitors
📈 Greatest impact in ESR1-mutant tumors
💊 Potential oral, well-tolerated option for post-CDK4/6 (2/5)

Dr. J Crown shared 5-year results from the NATALEE trial 🧬
Adjuvant ribociclib + aromatase inhibitors showed lasting benefit in HR+/HER2- early BC
✅ ~28% lower risk of recurrence or death
✅ Benefit seen even in node-neg (4/4)

Dr. S Johnston shared a 1st look at overall survival in the monarchE trial:

Abemaciclib + hormone therapy improved OS in node+ HR+/HER2- early BC
✅Risk of death reduced by15.8%

✅Metastases reduced (14% vs 20%)
✅First CDK4/6 inhibitor to show OS gain in adjuvant setting (3/4)

Dr. Fedro Peccatori gave a 5-year update from the POSITIVE Trial confirming it remains safe to pause (and later resume) hormone therapy to conceive for those with HR+ early BC.

Data showed:
✅ No rise in recurrence
✅ High pregnancy rate >76% & birth rate >90% (2/4)